Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
121
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland

Timo Purmonen1 Novartis Finland Oy, Espoo, Finland, [email protected]Correspondence[email protected]
,
Kari Puolakka2 South Karelia Central Hospital, Lappeenranta, Finland
,
Dinesh Mishra3 Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India
,
Praveen Gunda3 Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India
&
Janne Martikainen4 School of Pharmacy, University of Eastern Finland, Kuopio, Finland
Pages 159-168 | Published online: 15 Feb 2019

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yixiao Liu, Ling Xu, Xinrui Wang, Lijuan Wu, Ruifen Cai, Lujin Li & Qingshan Zheng. (2023) Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Review of Clinical Pharmacology 0:0, pages 1-10.
Read now
Fabiola Atzeni, Antonio Carriero, Laura Boccassini & Salvatore D’Angelo. (2021) Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and Therapy 10, pages 141-153.
Read now

Articles from other publishers (6)

G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini & A. Fassio. (2023) Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement. Reumatismo 75:1.
Crossref
Bente Glintborg, Ulf Lindström, Daniela Di Giuseppe, Sella Aarrestad Provan, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen, Johan K. Wallman, Kalle Aaltonen, Anna‐Mari Hokkanen, Dan Nordström, Tanja Schjødt Jørgensen, Rebekka Lund Hansen, Arni Jon Geirsson, Kathrine Lederballe Grøn, Niels Steen Krogh, Johan Askling, Lars Erik Kristensen & Lennart T. H. Jacobsson. (2022) One‐Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses . Arthritis Care & Research 74:5, pages 748-758.
Crossref
Peng Wang, Shuo Zhang, Binwu Hu, Weijian Liu, Xiao Lv, Songfeng Chen & Zengwu Shao. (2021) Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clinical Rheumatology 40:8, pages 3053-3065.
Crossref
Quang A. LeJenny H. KangSun LeeDimittri Delevry. (2020) Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1219-1231.
Crossref
George E Fragoulis & Stefan Siebert. (2020) Treatment strategies in axial spondyloarthritis: what, when and how?. Rheumatology 59:Supplement_4, pages iv79-iv89.
Crossref
. (2019) Secukinumab cost-effective option in ankylosing spondylitis. PharmacoEconomics & Outcomes News 822:1, pages 31-31.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.